Skip to main content
enGene Holdings Inc. logo

enGene Holdings Inc. — Investor Relations & Filings

Ticker · ENGN ISIN · CA29286M1059 LEI · 529900NE5JFN74BYXQ13 US Manufacturing
Open in API
Filings indexed 224 across all filing types
Latest filing 2023-09-30 Proxy Solicitation & In…
Country CA Canada
Listing US ENGN

About enGene Holdings Inc.

https://engene.com/

enGene Holdings Inc. is a clinical-stage biotechnology company developing non-viral gene therapies. The company's proprietary platform is designed for the local delivery of DNA-based immunotherapies directly to mucosal tissues and other organs. Its lead product candidate, EG-70 (detalimogene voraplasmid), is an intravesical therapy being evaluated for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The therapeutic approach aims to stimulate a patient's own immune system to attack tumor cells. By avoiding viral vectors, enGene seeks to create re-dosable genetic medicines that can be administered without the complexities and potential immunogenicity associated with viral-based systems, with the goal of making gene-based treatments more accessible.

Recent filings

Filing Released Lang Actions
424B3
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a proxy statement and prospectus related to a business combination (merger) between Forbion European Acquisition Corp. (FEAC) and enGene Holdings Inc. It includes detailed information about the business combination agreement, the proposed transactions, and the proposals to be voted on at an extraordinary general meeting of shareholders. The document is not a financial report, earnings release, or regulatory filing but rather a solicitation of shareholder votes and detailed information about the merger transaction. This fits the definition of a Proxy Solicitation & Information Statement (PSI).
2023-09-30 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-4. It references a specific filing (Form S-4) and requests regulatory action but does not contain financial data, report content, or detailed analysis. The document is short (1335 characters) and is a correspondence related to a regulatory filing process rather than the filing itself. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and correspondence with regulators that do not constitute a full report or filing type like a registration statement or financial report.
2023-09-28 English
Regulatory Filings 2023
Regulatory Filings Classification · 100% confidence The document is a letter from legal counsel responding to comments from the SEC staff regarding a Registration Statement on Form S-4. It discusses amendments to the Registration Statement and legal opinions filed as exhibits. The document is correspondence related to a regulatory filing process, specifically an amendment to a Form S-4 registration statement, and does not contain financial data, management discussion, or report content itself. It is not a full report but a regulatory correspondence and response to SEC comments. The document length is under 5,000 characters and is primarily a regulatory communication. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and response to SEC comments.
2023-09-26 English
S-4/A
Merger & Acquisition Classification · 100% confidence The document is a Form S-4/A Registration Statement filed with the SEC, which is used for registering securities in connection with mergers and acquisitions. It includes detailed information about a business combination agreement, proxy statement/prospectus for shareholder voting, and related merger transactions. The presence of a proxy statement and detailed merger terms indicates this is related to M&A activity. The document is not a simple announcement or a report of voting results but a comprehensive filing related to a merger transaction. Therefore, the appropriate classification is Merger & Acquisition (MA).
2023-09-26 English
425 Filing
Regulatory Filings
2023-09-15 English
Regulatory Filings 2023
Regulatory Filings
2023-09-11 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.